{"id":"injectable-buprenorphine","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Sweating"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine acts as a partial agonist at the mu-opioid receptor, meaning it produces submaximal effects compared to full agonists like heroin or morphine. This partial agonism provides analgesia and reduces withdrawal symptoms in opioid-dependent patients while having a built-in safety ceiling that limits respiratory depression risk. The injectable formulation allows for sustained therapeutic levels and improved medication adherence in opioid use disorder treatment.","oneSentence":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:06.056Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder (maintenance treatment)"},{"name":"Moderate to severe pain (analgesic use)"}]},"trialDetails":[{"nctId":"NCT04677114","phase":"PHASE2","title":"Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections","status":"COMPLETED","sponsor":"Laura Fanucchi","startDate":"2021-03-16","conditions":"Drug Use, Opioid-use Disorder","enrollment":71},{"nctId":"NCT06651177","phase":"PHASE2","title":"Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"T. John Winhusen, PhD","startDate":"2026-01-29","conditions":"Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe","enrollment":310},{"nctId":"NCT06576843","phase":"PHASE2","title":"INDV-6001 Multiple-Dose Pharmacokinetic Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2024-09-17","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":123},{"nctId":"NCT03911466","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":97},{"nctId":"NCT03911739","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2021-06-14","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":71},{"nctId":"NCT07469501","phase":"PHASE4","title":"Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-06","conditions":"Opioid Use Disorder, Fentanyl","enrollment":50},{"nctId":"NCT06726200","phase":"EARLY_PHASE1","title":"A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use","status":"RECRUITING","sponsor":"Rachel R. Luba","startDate":"2026-08","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT07439549","phase":"PHASE4","title":"Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Pouya Azar","startDate":"2026-02-18","conditions":"Opioid Use Disorder","enrollment":12},{"nctId":"NCT05991622","phase":"PHASE2","title":"Combined Injectable Treatment for HIV and OUD","status":"WITHDRAWN","sponsor":"Rhode Island Hospital","startDate":"2022-04-01","conditions":"Human Immunodeficiency Virus, Opioid Use Disorder","enrollment":""},{"nctId":"NCT06854029","phase":"PHASE4","title":"NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-06","conditions":"HIV Infections, Opioid Use Disorder, Incarceration; Lens","enrollment":300},{"nctId":"NCT04245423","phase":"NA","title":"The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-12-15","conditions":"Opioid-use Disorder, Mental Health Conditions","enrollment":567},{"nctId":"NCT04276259","phase":"PHASE4","title":"Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2020-10-19","conditions":"Major Depressive Disorder, Depression","enrollment":120},{"nctId":"NCT04995029","phase":"PHASE4","title":"Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2021-10-26","conditions":"Moderate to Severe Opioid-use Disorder","enrollment":785},{"nctId":"NCT07176351","phase":"PHASE4","title":"Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT04408313","phase":"PHASE2, PHASE3","title":"Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail","status":"ACTIVE_NOT_RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2020-10-28","conditions":"Opioid-use Disorder","enrollment":240},{"nctId":"NCT04375033","phase":"PHASE4","title":"A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-11-03","conditions":"Opioid Use Disorder","enrollment":952},{"nctId":"NCT06023459","phase":"PHASE3","title":"Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yih-Ing Hser","startDate":"2024-10-14","conditions":"Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders","enrollment":144},{"nctId":"NCT07296770","phase":"PHASE3","title":"An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-05-01","conditions":"Postsurgical Pain Management, Postsurgical Pain, Chronic, Opioid Use After Surgery","enrollment":126},{"nctId":"NCT04464980","phase":"PHASE2","title":"Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-06-08","conditions":"Opioid Use Disorder (OUD)","enrollment":1516},{"nctId":"NCT04345718","phase":"PHASE2, PHASE3","title":"EXHIT ENTRE Comparative Effectiveness Trial","status":"COMPLETED","sponsor":"Gavin Bart","startDate":"2021-08-09","conditions":"Substance Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe","enrollment":344},{"nctId":"NCT06416020","phase":"NA","title":"Integrating MOUD in Nonmedical Community Settings (Better Together)","status":"NOT_YET_RECRUITING","sponsor":"Howard University","startDate":"2026-01-26","conditions":"Opioid Use Disorder","enrollment":400},{"nctId":"NCT05262270","phase":"PHASE2","title":"Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-04-18","conditions":"Cocaine Use Disorder","enrollment":427},{"nctId":"NCT04600414","phase":"NA","title":"Collaborating to Heal Addiction and Mental Health in Primary Care","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-11-16","conditions":"Opioid-use Disorder, Mental Health Disorder","enrollment":254},{"nctId":"NCT06051890","phase":"PHASE4","title":"Assessing Optimal XRB Initiation Points in Jail","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-06-02","conditions":"Opioid Use Disorder","enrollment":200},{"nctId":"NCT04454411","phase":"PHASE2","title":"Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2022-08-01","conditions":"Opioid Dependence","enrollment":3},{"nctId":"NCT05528848","phase":"PHASE1","title":"Multi-System Analysis of Opioid Receptor Binding","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-09-20","conditions":"Healthy, Opioid Use Disorder","enrollment":60},{"nctId":"NCT03918850","phase":"PHASE3","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":140},{"nctId":"NCT04219540","phase":"PHASE4","title":"Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-01-07","conditions":"Opioid-use Disorder","enrollment":675},{"nctId":"NCT04180020","phase":"NA","title":"Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-08-18","conditions":"Opioid-use Disorder","enrollment":171},{"nctId":"NCT03993392","phase":"PHASE4","title":"SUBLOCADE Rapid Initiation Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-08-29","conditions":"Opioid-use Disorder","enrollment":26},{"nctId":"NCT04060654","phase":"PHASE4","title":"SUBLOCADE Rapid Initiation Extension Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-10-21","conditions":"Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate","enrollment":17},{"nctId":"NCT05283304","phase":"PHASE2","title":"Monthly Injectable BUP for MA Use Disorder (MURB) Trial","status":"TERMINATED","sponsor":"Madhukar H. Trivedi, MD","startDate":"2023-03-24","conditions":"Methamphetamine-dependence","enrollment":18},{"nctId":"NCT06880718","phase":"PHASE4","title":"Injectable Buprenorphine in Prison: a Preference Trial","status":"NOT_YET_RECRUITING","sponsor":"Lifespan","startDate":"2025-06","conditions":"Opioid Use Disorder, Incarceration, Medications for Opioid Use Disorder","enrollment":60},{"nctId":"NCT03221309","phase":"","title":"Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2017-05-01","conditions":"HCV, Buprenorphine, PreP","enrollment":198},{"nctId":"NCT03747341","phase":"PHASE1","title":"Buprenorphine-Fentanyl Interaction Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2018-03-22","conditions":"Healthy, Opioid Use","enrollment":22},{"nctId":"NCT04352166","phase":"PHASE2","title":"Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder","status":"SUSPENDED","sponsor":"Frances R Levin","startDate":"2020-12-15","conditions":"Opioid-use Disorder","enrollment":40},{"nctId":"NCT04225598","phase":"PHASE2","title":"Emergency Department-Initiated Buprenorphine Validation Network Trial","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-07-08","conditions":"Opioid-use Disorder","enrollment":2000},{"nctId":"NCT05704543","phase":"PHASE4","title":"Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2023-03-01","conditions":"Opioid Use Disorder","enrollment":132},{"nctId":"NCT04480554","phase":"PHASE2","title":"Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-01-30","conditions":"Opioid-use Disorder, HIV-1-infection, Immune Activation","enrollment":225},{"nctId":"NCT04575324","phase":"NA","title":"Project STAMINA (Syringe Service Telemedicine Access for Medication-assisted Intervention Through NAvigation)","status":"COMPLETED","sponsor":"Chestnut Health Systems","startDate":"2020-08-24","conditions":"Opioid-use Disorder","enrollment":275},{"nctId":"NCT06354465","phase":"","title":"Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews","status":"RECRUITING","sponsor":"Lifespan","startDate":"2023-07-01","conditions":"Opioid Use Disorder, Criminal Justice, Treatment Adherence and Compliance","enrollment":25},{"nctId":"NCT05481112","phase":"PHASE4","title":"Assessing Optimal XR-Buprenorphine Initiation Points in Jail","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2023-11-01","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT05164549","phase":"PHASE3","title":"Extended-release Pharmacotherapy for Opioid Use Disorder","status":"COMPLETED","sponsor":"King's College London","startDate":"2019-08-06","conditions":"Opiate Substitution Treatment","enrollment":342},{"nctId":"NCT03845894","phase":"PHASE4","title":"Interscalene Block With Liposomal Bupivacaine vs. Interscalene Block With Bupivacaine and Adjuvants","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2020-03-03","conditions":"Shoulder Arthroplasty","enrollment":25},{"nctId":"NCT03976258","phase":"","title":"Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2017-07-14","conditions":"HIV Infection, Opioid-use Disorder, Cardiovascular Diseases","enrollment":190},{"nctId":"NCT04762537","phase":"NA","title":"Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2021-03-16","conditions":"Opioid-use Disorder","enrollment":415},{"nctId":"NCT03852628","phase":"PHASE2","title":"Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD","status":"TERMINATED","sponsor":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","startDate":"2019-05-20","conditions":"Post Traumatic Stress Disorder, Alcohol Abuse","enrollment":69},{"nctId":"NCT04254081","phase":"PHASE4","title":"Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-05-28","conditions":"Procedural Pain, Buprenorphine, Adjuvants, Anesthesia","enrollment":57},{"nctId":"NCT03647774","phase":"PHASE4","title":"Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery","status":"COMPLETED","sponsor":"Lars Tanum","startDate":"2018-08-01","conditions":"Opioid-use Disorder","enrollment":317},{"nctId":"NCT04815590","phase":"","title":"Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose","status":"UNKNOWN","sponsor":"BC Centre on Substance Use","startDate":"2022-10-17","conditions":"Opioid-Use Disorder, Opioid Overdose","enrollment":40},{"nctId":"NCT05594121","phase":"PHASE4","title":"Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder","status":"UNKNOWN","sponsor":"Royal Victoria Hospital, Canada","startDate":"2022-12","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":90},{"nctId":"NCT03933865","phase":"PHASE1","title":"Acute Pain Management in Patients on Opioid Replacement Therapy","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2018-10-31","conditions":"Opioid-use Disorder, Pain, Acute","enrollment":1},{"nctId":"NCT04577144","phase":"","title":"An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term","status":"TERMINATED","sponsor":"Indivior Inc.","startDate":"2020-09-20","conditions":"Opioid Use Disorder","enrollment":216},{"nctId":"NCT05549492","phase":"PHASE1","title":"Transversus Abdominis Plane Block With or Without Buprenorphine After Inguinal Hernia Surgery","status":"COMPLETED","sponsor":"Egymedicalpedia","startDate":"2021-01-01","conditions":"Inguinal Hernia, Pain, Postoperative","enrollment":64},{"nctId":"NCT04139213","phase":"PHASE2, PHASE3","title":"Medication Maintenance Therapy in Community Pharmacy Settings","status":"UNKNOWN","sponsor":"Lifespan","startDate":"2019-07-25","conditions":"Opioid-use Disorder","enrollment":250},{"nctId":"NCT02543944","phase":"PHASE2, PHASE3","title":"Improving Treatment Outcomes for Prescription Opioid Dependence","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2016-02","conditions":"Drug Dependence","enrollment":117},{"nctId":"NCT03744663","phase":"PHASE2","title":"Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2022-06","conditions":"Opioid Use","enrollment":""},{"nctId":"NCT03818399","phase":"PHASE3","title":"Virginia Opioid Overdose Treatment InitiatVE","status":"TERMINATED","sponsor":"Virginia Commonwealth University","startDate":"2019-01-04","conditions":"Opioid Use Disorder","enrollment":19},{"nctId":"NCT03113409","phase":"PHASE2, PHASE3","title":"Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2017-06-01","conditions":"Opioid-use Disorder","enrollment":10},{"nctId":"NCT03604159","phase":"PHASE4","title":"XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-24","conditions":"Opioid Dependence","enrollment":52},{"nctId":"NCT04122755","phase":"PHASE1","title":"Single Ascending Dose Study of ALA-1000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2019-09-16","conditions":"Opioid-use Disorder","enrollment":59},{"nctId":"NCT01843023","phase":"PHASE4","title":"Extended Release Naltrexone for Opioid-Dependent Youth","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2013-06","conditions":"Drug Dependence","enrollment":288},{"nctId":"NCT00270257","phase":"PHASE3","title":"Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections, Opioid-Related Disorders","enrollment":1251},{"nctId":"NCT01402492","phase":"PHASE2, PHASE3","title":"Cocaine Use Reduction With Buprenorphine","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-09","conditions":"Cocaine Dependence","enrollment":302},{"nctId":"NCT05090761","phase":"NA","title":"Serratus Anterior Plane Block With and Without Adjuvants in Video-assisted Thoracoscopy","status":"UNKNOWN","sponsor":"Wayne State University","startDate":"2021-10-12","conditions":"Post Operative Pain, Acute","enrollment":120},{"nctId":"NCT02946073","phase":"PHASE3","title":"Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2016-09","conditions":"Chronic Lower Back Pain, Chronic Pain","enrollment":1053},{"nctId":"NCT05003765","phase":"NA","title":"Are Superficial Parasternal Intercostal Plane (SPIP) Blocks With Bupivacaine and With or Without Adjuvants Helpful for Post-operative Pain After Coronary Artery Bypass Grafting?","status":"UNKNOWN","sponsor":"Wayne State University","startDate":"2020-08-06","conditions":"Post-operative Pain Management","enrollment":200},{"nctId":"NCT01999946","phase":"PHASE4","title":"Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-06-27","conditions":"Heroin Dependence, Opioid-Related Disorders","enrollment":217},{"nctId":"NCT03861338","phase":"PHASE1, PHASE2","title":"An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2019-03-01","conditions":"Opioid-use Disorder","enrollment":11},{"nctId":"NCT04523792","phase":"PHASE3","title":"Virginia Opioid Treatment-Emergency Department","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"2021-01-01","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT03752528","phase":"","title":"Evaluation of Long-term Buprenorphine Plasma Exposure","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-02-19","conditions":"Opioid-use Disorder","enrollment":53},{"nctId":"NCT02672111","phase":"PHASE3","title":"Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2015-11","conditions":"Opioid Use Disorder","enrollment":228},{"nctId":"NCT02710526","phase":"PHASE2","title":"Phase II Pharmacokinetics Study of CAM2038","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2015-02","conditions":"Opioid Use Disorder, Chronic Pain","enrollment":66},{"nctId":"NCT02583243","phase":"","title":"Project BEST: Buprenorphine Entry Into Substance Abuse Treatment","status":"COMPLETED","sponsor":"Yale University","startDate":"2005-05","conditions":"Opioid-related Disorders, HIV Infections, Hepatitis C, Chronic","enrollment":209},{"nctId":"NCT02294253","phase":"PHASE2, PHASE3","title":"Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-09","conditions":"Opioid Dependence","enrollment":30},{"nctId":"NCT03809143","phase":"PHASE3","title":"Community Studies of Long Acting Buprenorphine (CoLAB)","status":"UNKNOWN","sponsor":"The University of New South Wales","startDate":"2019-05-22","conditions":"Opioid Dependence","enrollment":100},{"nctId":"NCT02611752","phase":"PHASE2","title":"A Multiple Dose Opioid Challenge Study","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2015-10","conditions":"Moderate or Severe Opioid Use Disorder","enrollment":47},{"nctId":"NCT02651584","phase":"PHASE3","title":"Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2015-12","conditions":"Opioid Use Disorders","enrollment":428},{"nctId":"NCT03766893","phase":"EARLY_PHASE1","title":"Medication Maintenance Therapy in Community Pharmacy Settings","status":"COMPLETED","sponsor":"Lifespan","startDate":"2018-09-01","conditions":"Opioid-use Disorder","enrollment":11},{"nctId":"NCT03604861","phase":"","title":"An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-08","conditions":"Opioid-use Disorder, Opioid-related Disorders","enrollment":534},{"nctId":"NCT02537574","phase":"PHASE3","title":"Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2015-08","conditions":"Opioid Use Disorder","enrollment":380},{"nctId":"NCT02896296","phase":"PHASE3","title":"Open-Label Treatment Extension Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2016-08-17","conditions":"Opioid Use Disorder, Opioid-related Disorders","enrollment":208},{"nctId":"NCT02593474","phase":"PHASE1","title":"Medication-Assisted Treatment for Youth With Substance Use Disorders","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2015-09","conditions":"Opioid Use Disorder, Opioid Dependence","enrollment":11},{"nctId":"NCT03254459","phase":"PHASE2","title":"Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2017-09-12","conditions":"Pain, Postoperative","enrollment":100},{"nctId":"NCT01717963","phase":"PHASE3","title":"Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway","status":"COMPLETED","sponsor":"University of Oslo","startDate":"2012-10","conditions":"Opioid Dependence","enrollment":166},{"nctId":"NCT01708707","phase":"PHASE2","title":"Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)","status":"COMPLETED","sponsor":"Pediatrix","startDate":"2012-12","conditions":"Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome","enrollment":29},{"nctId":"NCT01377610","phase":"PHASE1","title":"Improved Strategies for Outpatient Opioid Detoxification","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2011-06","conditions":"Opioid Dependence","enrollment":150},{"nctId":"NCT02044094","phase":"PHASE2","title":"Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2013-11","conditions":"Opioid Use Disorder","enrollment":39},{"nctId":"NCT01761110","phase":"NA","title":"Pilot Test of a Community-based Buprenorphine Treatment Intervention","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2012-12","conditions":"Opioid Dependence, Injection Drug Use","enrollment":77},{"nctId":"NCT02991404","phase":"EARLY_PHASE1","title":"Single Injection Adductor Canal Block Versus Continuous Adductor Canal Infusion for Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-02-17","conditions":"Total Knee Arthroplasty, Pain, Postoperative, Adductor Canal Block","enrollment":60},{"nctId":"NCT02510014","phase":"PHASE3","title":"Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-07-27","conditions":"Opioid Use Disorder, Opioid-related Disorders","enrollment":775},{"nctId":"NCT01738503","phase":"PHASE2","title":"Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-10","conditions":"Opioid Related Disorder","enrollment":124},{"nctId":"NCT02357901","phase":"PHASE3","title":"Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-01-28","conditions":"Opioid Dependence, Opioid Related Disorders","enrollment":665},{"nctId":"NCT02372591","phase":"PHASE1","title":"Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal Pain","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2015-08","conditions":"Opioid-Related Disorders, Chronic Pain","enrollment":14},{"nctId":"NCT01642030","phase":"PHASE1","title":"Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2013-08","conditions":"Opioid Dependence, Pain, Addiction","enrollment":132},{"nctId":"NCT01136356","phase":"PHASE1, PHASE2","title":"A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2010-07","conditions":"Opioid Abuse, Opioid Dependence","enrollment":12},{"nctId":"NCT02559973","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-09","conditions":"Opioid Use Disorder","enrollment":47},{"nctId":"NCT00134914","phase":"NA","title":"Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1996-08","conditions":"Opioid-Related Disorders","enrollment":10},{"nctId":"NCT00134875","phase":"NA","title":"Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-12","conditions":"Opioid-Related Disorders","enrollment":9},{"nctId":"NCT03002961","phase":"PHASE1","title":"Single Ascending Dose Study of RBP-6000","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-07","conditions":"Opioid Use Disorder","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":112,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Direct-to-inject","Brixadi","Sublocade","Long-acting injectable buprenorphine","XR-BUP (Brixadi)"],"phase":"marketed","status":"active","brandName":"Injectable buprenorphine","genericName":"Injectable buprenorphine","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression. Used for Opioid use disorder (maintenance treatment), Moderate to severe pain (analgesic use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}